Sareum Holdings PLC Sierra Oncology Q3 2018 Results (8061G)
08 November 2018 - 11:28PM
UK Regulatory
TIDMSAR
RNS Number : 8061G
Sareum Holdings PLC
08 November 2018
(AIM: SAR) 8 November 2018
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Sareum notes Sierra Oncology has reported Third Quarter 2018
Results
Sareum Holdings plc (AIM: SAR), the specialist cancer drug
discovery and development business, notes that Sierra Oncology, the
licence holder advancing clinical cancer candidate SRA737, has
reported its Third Quarter 2018 Results including reference to the
ongoing development of SRA737.
In the statement, Sierra CEO Nick Glover commented that Sierra
has made substantial progress enrolling genetically-selected
patients into the indication-specific cohorts of two SRA737 trials,
with a focus on recruiting patients with High Grade Serous Ovarian
Cancer (HGSOC). Preliminary efficacy results from these trials are
expected to be reported in the first half of 2019.
Sierra has also continued preparing for the initiation of a
Phase 1b/2 trial of SRA737 with the PARP inhibitor niraparib, which
will evaluate this combination in subjects with metastatic
castration-resistant prostate cancer (mCRPC).
Title of announcement: Sierra Oncology Reports Third Quarter
2018 Results
Link to announcement:
https://www.prnewswire.com/news-releases/sierra-oncology-reports-third-quarter-results-300744943.html
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases and cancers. TYK2 and JAK1 have roles in pro-inflammatory
responses in autoimmune diseases (e.g. psoriasis, rheumatoid
arthritis, inflammatory bowel diseases and lupus) and tumour cell
proliferation in certain cancers (e.g. T-cell acute lymphoblastic
leukaemia and some solid tumours). The Company is targeting first
human clinical trials in each indication in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
QRTBPBTTMBTMBJP
(END) Dow Jones Newswires
November 08, 2018 07:28 ET (12:28 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024